<DOC>
	<DOCNO>NCT02680041</DOCNO>
	<brief_summary>This prospective study enroll 330 men PSA-persistent PSA-recurrent prostate cancer curative-intent primary therapy negative equivocal finding standard-of-care imaging . Consenting participant image 18F-fluciclovine PET/CT . Site clinicians manage study subject per standard practice document change treatment base review 18F-fluciclovine PET/CT finding . All participant follow 6 month , clinical data collect study . An interdisciplinary panel provide expert guidance local reader request . The final reporting PET/CT scan single report local reader follow discussion .</brief_summary>
	<brief_title>18F Fluciclovine ( FACBC ) PET/CT Patients With Rising PSA After Initial Prostate Cancer Treatment</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>History histologically confirm adenocarcinoma prostate post curativeintent local treatment ( radical prostatectomy , local radiotherapy , brachytherapy ) . Suspicion recurrent prostate carcinoma previous presumed definitive therapy organ confine disease define : Post prostatectomy : Detectable rise PSA level &gt; 0.2 ng/mL second confirmatory level &gt; 0.2 ng/mL Post nonprostatectomy : PSA rise â‰¥ 2ng/mL nadir Negative equivocal finding standardofcare image restaging disease previous 60 day consist : Wholebody 99mTc bone scintigraphy NaF PETCT ; either CT MRI pelvis ( abdomen pelvis ) . Being consider salvage therapy Any nonsurgical local treatment previous cryotherapy , external beam radiation , HiFU ( Ultrasound ) must occur least 1 year past . Previous brachytherapy treatment occur least 2 year past Ability understand willingness sign write informed consent . Ongoing treatment systemic therapy intend treatment prostate cancer ( e.g. , antiandrogen LHRH agonist antagonist ) Androgen deprivation therapy ( ADT ) past 3 month History bilateral orchidectomy Inability tolerate 18Ffluciclovine PET/CT</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>